Phenotypic screening in cancer drug discovery - past, present and future.
about
Bridging academic science and clinical research in the search for novel targeted anti-cancer agentsCellular imaging: a key phenotypic screening strategy for predictive toxicologyDiversity-oriented synthetic strategies applied to cancer chemical biology and drug discoveryStrength and specificity of the CMBA screening platform for bioactive molecules discoveryRing-Shaped Microlanes and Chemical Barriers as a Platform for Probing Single-Cell MigrationSelective small-molecule inhibition of an RNA structural elementA 3D-microtissue-based phenotypic screening of radiation resistant tumor cells with synchronized chemotherapeutic treatmentImproving drug discovery with high-content phenotypic screens by systematic selection of reporter cell linesEpigenetic assays for chemical biology and drug discovery.Flow Cytometry: Impact on Early Drug DiscoveryIdentification of cancer-cytotoxic modulators of PDE3A by predictive chemogenomics.Bioinformatics and Drug Discovery.Recent advances in quantitative high throughput and high content data analysis.EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.Screening and identification of novel biologically active natural compounds.Challenges and opportunities toward enabling phenotypic screening of complex and 3D cell models.Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profilingThermal proteome profiling for unbiased identification of direct and indirect drug targets using multiplexed quantitative mass spectrometry.High-throughput imaging: Focusing in on drug discovery in 3D.Characterization of Cardiac Glycoside Natural Products as Potent Inhibitors of DNA Double-Strand Break Repair by a Whole-Cell Double Immunofluorescence Assay.The Power of Sophisticated Phenotypic Screening and Modern Mechanism-of-Action Methods.Identification of protein binding partners of small molecules using label-free methods.Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes.Identification of Novel Human Breast Carcinoma (MDA-MB-231) Cell Growth Modulators from a Carbohydrate-Based Diversity Oriented Synthesis Library.Plant Chemical Genetics: From Phenotype-Based Screens to Synthetic Biology.Phenylpyrrolidine structural mimics of pirfenidone lacking antifibrotic activity: A new tool for mechanism of action studies.Characterizing the Covalent Targets of a Small Molecule Inhibitor of the Lysine Acetyltransferase P300.A Perspective on Implementing a Quantitative Systems Pharmacology Platform for Drug Discovery and the Advancement of Personalized Medicine.ARTIK-52 induces replication-dependent DNA damage and p53 activation exclusively in cells of prostate and breast cancer origin.Accurate Morphology Preserving Segmentation of Overlapping Cells based on Active ContoursComparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surfaceLabel-free target identification using in-gel fluorescence difference via thermal stability shift.Addressing the right targets in oncology: challenges and alternative approaches.The Discovery Channel: microfluidics and microengineered systems in drug screening.In silico tools used for compound selection during target-based drug discovery and development.Affinity purification in target identification: the specificity challenge.Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.Discovery of novel drug targets and their functions using phenotypic screening of natural products.Drug repurposing in oncology--patient and health systems opportunities.Target identification of natural products and bioactive compounds using affinity-based probes.
P2860
Q26771396-79095437-019D-4247-96A8-BA33088A8E3EQ26781577-8CF097A2-9AF5-46CB-B879-4C476FBBFAADQ26829081-CC422A0D-51A5-4C5C-9207-86068CB5CB8FQ27014820-20887787-0E52-4716-BECB-D4C282613DEFQ27349210-9F90F7DC-52A7-48D5-BC8A-235AE7DCFED9Q27702218-134D0090-3CEE-4DBA-9909-24A596A20942Q28641649-0AD74E03-5D0A-474E-B5F4-F4D4D25420F4Q28834223-B117B555-4E20-4561-B339-A7C6772C538EQ30358152-5CE3097F-E18E-428F-8A4C-497731F2237CQ30380311-60FC3A20-5CC1-4BCA-9FDB-BCD15B96C760Q30381467-116AAA38-C819-4A1F-AD60-FE0E1247D600Q30395256-D79DF7D2-1684-4D26-A413-7A46242F56BCQ31049930-6A94E208-BAAB-44FE-9AA6-87E5EC8DAAE3Q33276007-E95B8707-1DBF-409A-B42A-2A6A3C9B8AC9Q33777835-1AEF4A7F-BE8F-4253-92BA-603B1411948DQ35602409-1087D5CD-D2D1-4190-9F40-53134C06E246Q35728113-21F3BACA-4B44-4B36-BDDA-6F2D9F549AFBQ35778631-D0C1BE61-D625-44B8-BC32-E40CED3C07DCQ35853192-1EB48B26-C486-493F-A486-8459DDF1DE4CQ35940003-9BA63CA9-0396-4844-A015-A86F9FC2B9DDQ35942602-D45E976E-1A4E-4DB7-B393-BB2B28C57BAAQ36110953-F765A55D-5C12-4C79-BD16-DA7B9F96D388Q36112726-4A07DD10-4DF8-4A0F-AACD-F5F1D40C961BQ36172912-BEA91A16-B8B3-48E3-8283-57D1FC856799Q36301455-0B7A0B68-01FA-403E-A137-E3A2D622724AQ36391459-DA870A94-A133-44CA-86D4-17E8A2929432Q36579846-43F860AC-7384-48F9-88EA-59E9360565EFQ37029832-82993ACB-9968-4910-A5FD-B7CD40C30D27Q37091948-FAD75186-8CC7-4E5B-9B22-0FFFA1F12DB3Q37211051-D9A990EC-2E2A-42C2-B6B1-B4DEEC864734Q37686308-682D761E-7CB7-472E-82DC-BD9976D1CD2DQ37725007-5EA398D3-7F95-43D2-9656-A7AE198B20DEQ38329647-404055B3-4D73-4065-A01F-CDB9DD009713Q38353846-84113CA8-A6D7-4A61-B929-5304C21C33BAQ38465124-18AD688A-AB11-4495-B311-C92507C43363Q38561919-71E07EBF-2992-490A-9242-15DE96B9F1DCQ38580461-1629CCFB-C813-4434-925F-136F30705D3FQ38585751-CBED5C96-DB1A-475B-AAD8-5EC4848A4063Q38611707-E0BC550B-F085-4746-9FCF-4E826091C15DQ38637266-94AAD7B2-36B5-4F1B-9266-FFC0535F5C93
P2860
Phenotypic screening in cancer drug discovery - past, present and future.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Phenotypic screening in cancer drug discovery - past, present and future.
@ast
Phenotypic screening in cancer drug discovery - past, present and future.
@en
Phenotypic screening in cancer drug discovery - past, present and future.
@nl
type
label
Phenotypic screening in cancer drug discovery - past, present and future.
@ast
Phenotypic screening in cancer drug discovery - past, present and future.
@en
Phenotypic screening in cancer drug discovery - past, present and future.
@nl
prefLabel
Phenotypic screening in cancer drug discovery - past, present and future.
@ast
Phenotypic screening in cancer drug discovery - past, present and future.
@en
Phenotypic screening in cancer drug discovery - past, present and future.
@nl
P2093
P356
P1476
Phenotypic screening in cancer drug discovery - past, present and future.
@en
P2093
David Bailey
Joachim Rudolph
John G Moffat
P2888
P304
P356
10.1038/NRD4366
P577
2014-07-18T00:00:00Z
P6179
1004564684